The strategy is all spelled out and perfectly explained in multiple presentations via a very capable CEO.
$50m market cap for a company that has the opportunity to make a major difference in one of the worlds most common chronic diseases......the clowns, detractors, down-rappers and hotcopper Medical professors polute this forum with factually incorrect information for months.
then as soon as price starts to recover from a major irrational sell-off they claim insider trading.
IMO (not advice, DYOR), with a UK launch in Q4, and US next year, anything under 15c is a free kick.
DYOR into why Australia is a test market, that was never going to be as successful as other major markets where greater support is available (government, insurance, clinical, commercial).....
Given we are dealing with preventative healthcare and changing behaviours, this top down support is a critical element to the company’s success.
RSH Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
